<DOC>
	<DOCNO>NCT01500408</DOCNO>
	<brief_summary>Biogen Idec develop novel process manufacture Interferon beta-1a ( INFB ) , active ingredient Avonex® , include fetal bovine serum ( FBS ) . This bioequivalence study conduct confirm pharmacokinetic ( PK ) pharmacodynamic ( PD ) comparability Interferon beta-1a produce currently approve serum-containing process Interferon beta-1a produce new serum-free manufacturing process .</brief_summary>
	<brief_title>Demonstrate Bioequivalence Interferon Beta-1a ( INFB ) Manufactured Two Different Processes Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>1 . Ability understand purpose risk study provide sign date informed consent authoriziation use protect health information ( PHI ) accordance national local subject privacy regulation . 2 . Must healthy male females 18 45 year old , inclusive , time informed consent . 3 . Must body mass index ( BMI ) 18.5 30.0 kg/ m2 , inclusive , minimum body weight 50.0 kg Screening Day1 Baseline . 4 . Subjects childbearing potential must practice effective contraception study willing able continue contraception 30 day last dose study treatment . 1 . Known history human immunodeficiency virus ( HIV ) . 2 . Positive test result Screening hepatitis C antibody ( HCV Ab ) current hepatitis B infection ( define positive hepatitis surface antigen [ HBcAb ] Screening ) . Subjects immunity hepatitis B either active vaccination ( define negative HBsAg , positive hepatitis B surface anitbody [ HBsAg ] , negative HBcAb ) previous natural infection ( define negative HBsAg , positive HBsAb immunoglobulin G , positiveHBcAb ) eligible participate study ( definition base Centers Disease Control Prevention interpretation hepatitis B serology panel ) . 3 . Subjects history malignant disease , include solid tumor hematologic malignancy ( except basal cell squamos cell carcinoma skin completely excise consider cure ) . 4 . History severe allergic anaphylactic reaction . 5 . Known allergy component IFN B1a formulation , include dry rubber allergy . 6 . History clinically significant cardiac , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , major disease , determine Investigator . 7 . History seizure disorder unexplained blackout . 8 . History suicidal ideation episode clinically severe depression ( determined Investigator ) . 9 . Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( pneumonia , septicemia ) , discretion Investigator , within 3 month prior Day 1 . 10 . History drug alcohol abuse ( define Investigator ) within 6 month prior Screening . 11 . Positive test drug alcohol Screening baseline ( Day1 ) . 12 . Alcohol use within 48 hour prior Day 1 . Subjects must willing restrict alcohol use throughout participation study . Subjects may consume 1 alcoholic beverage per day study 1 alcoholic beverage define ≤8 ounce beer ≤4 ounce wine . 13 . Fever ( body temperature &gt; 38°C ) symptomatic viral bacterial infection ( include upper respiratory infection ) within 1 week prior Day 1 . 14 . Clinically significant abnormal clinical laboratory test value , determine Investigator , value alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , creatinine upper limit normal , value platelet hemoglobin low limit normal , normal range value white blood cell , serum sodium , serum potassium . 15 . Any previous treatment interferon product , include investigational use . 16 . History hypersensitivity intolerance acetaminophen ( paracetamol ) , ibuprofen , naproxen , aspirin would preclude use least 1 study . 17 . Prior treatment investigational drug within 30 day prior Day 1 , within 5 halflives drug , whichever longer . 18 . Treatment medication include overthecounter ( OTC ) product within 48 hour prior Day 1 , except follow treatment , allow : contraceptive , hormone replacement therapy ( HRT ) , local , nonsystemically absorbed steroid ( i.e. , topical , nasal/inhaled ) , acetaminophen ( paracetamol ) , ibuprofen , naproxen , and/or aspirin . 19 . Female subject pregnant currently breastfeed positive pregnancy test result . 20 . Vaccinations within 4 week prior Day 1 . 21 . Blood donation ( 1 unit ) within 1 month prior Day 1 . 22 . Current enrollment study treatment disease study . 23 . Inability comply study requirement . 24 . Other unspecified reason , opinion Investigator Biogen Idec , make subject unsuitable enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>